Clinical trial announcements, orphan-drug designation and more: check out our round-up of the biggest news from the neuroscience and neurology industries this week.
The latest study assessing the drug erenumab has demonstrated promising results for migraine sufferers who failed to respond to prior treatments.
As we begin a new year on Neuro Central, we’re taking this opportunity to look back at some of the highlights across neuroscience and neurology in 2017.
Here at Neuro Central we’re taking a look back at some of the biggest developments in neuroscience and neurology over the past year.
A study at University Hospital Mannheim and Heidelberg University has indicated that migraine sufferers have significantly higher concentrations of sodium present in their cerebrospinal fluid than non-sufferers.
Results from two Phase III clinical trials for erenumab and fremanezumab show that the monoclonal antibody therapies can cut frequency of migraine attacks in half.
Data from a head-to-head, open-label study were presented at the 18th Congress of the International Headache Society in Vancouver (Canada, 7–10 September 2017).
Participants receiving the antibody treatment were also able to take less additional migraine medication compared with those in the placebo group.
Research presented at the Congress of the European Academy of Neurology 2017 confirms that cannabinoids are as suitable for preventing migraine attacks as other pharmaceutical treatments.
A new study has indicated that a wireless patch on the arm that provides electrical stimulation could be as effective in reducing migraine pain as conventional drugs.